Home/Pipeline/Elyea (relugolix combo)

Elyea (relugolix combo)

Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain

ApprovedLaunched / Commercial GrowthN/A

Key Facts

Indication
Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain
Phase
Approved
Status
Launched / Commercial Growth
Company

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

View full company profile